Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 1
2018 2
2019 4
2020 3
2021 1
2022 3
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean natsuaki takeda (34 results)?
Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
Matsumoto J, Iwata N, Watari S, Ushio S, Shiromizu S, Takeda T, Hamano H, Kajizono M, Araki M, Nasu Y, Ariyoshi N, Zamami Y. Matsumoto J, et al. Among authors: takeda t. Eur Urol Focus. 2023 Jan;9(1):141-144. doi: 10.1016/j.euf.2022.07.003. Epub 2022 Jul 29. Eur Urol Focus. 2023. PMID: 35915038
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
Torigoe H, Shien K, Takeda T, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Sakaguchi M, Tomida S, Tsukuda K, Miyoshi S, Toyooka S. Torigoe H, et al. Among authors: takeda t. Cancer Sci. 2018 May;109(5):1493-1502. doi: 10.1111/cas.13571. Epub 2018 Apr 15. Cancer Sci. 2018. PMID: 29532558 Free PMC article.
Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
Yoshioka T, Shien K, Takeda T, Takahashi Y, Kurihara E, Ogoshi Y, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H, Soh J, Fujiwara T, Toyooka S. Yoshioka T, et al. Among authors: takeda t. Cancer Sci. 2019 Aug;110(8):2549-2557. doi: 10.1111/cas.14089. Epub 2019 Jun 24. Cancer Sci. 2019. PMID: 31162771 Free PMC article.
Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.
Miyauchi S, Shien K, Takeda T, Araki K, Nakata K, Miura A, Takahashi Y, Kurihara E, Ogoshi Y, Namba K, Suzawa K, Yamamoto H, Okazaki M, Soh J, Tomida S, Yamane M, Sakaguchi M, Toyooka S. Miyauchi S, et al. Among authors: takeda t. Anticancer Res. 2020 May;40(5):2667-2673. doi: 10.21873/anticanres.14237. Anticancer Res. 2020. PMID: 32366411 Free article.
YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
Fujihara M, Shien T, Shien K, Suzawa K, Takeda T, Zhu Y, Mamori T, Otani Y, Yoshioka R, Uno M, Suzuki Y, Abe Y, Hatono M, Tsukioki T, Takahashi Y, Kochi M, Iwamoto T, Taira N, Doihara H, Toyooka S. Fujihara M, et al. Among authors: takeda t. Int J Mol Sci. 2021 Nov 26;22(23):12809. doi: 10.3390/ijms222312809. Int J Mol Sci. 2021. PMID: 34884609 Free PMC article.
18 results